mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.

about

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.

Item

http://www.wikidata.org/entity/Q49787386

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.

@en

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.

@nl

type

Item

label

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.

@en

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.

@nl

prefLabel

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.

@en

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.

@nl

P1476

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.

@en

P2093

David A Fruman

http://www.w3.org/2001/XMLSchema#string

Lee-Or Herzog

http://www.w3.org/2001/XMLSchema#string

Moran Gotesman

http://www.w3.org/2001/XMLSchema#string

Sarah K Tasian

http://www.w3.org/2001/XMLSchema#string

Sharmila Mallya

http://www.w3.org/2001/XMLSchema#string

Thanh-Trang T Vo

http://www.w3.org/2001/XMLSchema#string

Tiffeny Tea

http://www.w3.org/2001/XMLSchema#string

P2860

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.

High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL.

P304

6562-6571

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24020

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marina Konopleva

P577

2018-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29464092

http://www.w3.org/2001/XMLSchema#string

P932

5814232

http://www.w3.org/2001/XMLSchema#string